NEOS Investment Management LLC Buys 35,641 Shares of Bristol Myers Squibb Company $BMY

NEOS Investment Management LLC boosted its stake in Bristol Myers Squibb Company (NYSE:BMY) by 13.2% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 306,115 shares of the biopharmaceutical company’s stock after acquiring an additional 35,641 shares during the quarter. NEOS Investment Management LLC’s holdings in Bristol Myers Squibb were worth $13,806,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Arvest Bank Trust Division raised its stake in shares of Bristol Myers Squibb by 7.1% in the 3rd quarter. Arvest Bank Trust Division now owns 12,178 shares of the biopharmaceutical company’s stock valued at $549,000 after purchasing an additional 804 shares during the period. GSA Capital Partners LLP grew its holdings in shares of Bristol Myers Squibb by 30.1% during the third quarter. GSA Capital Partners LLP now owns 61,578 shares of the biopharmaceutical company’s stock worth $2,777,000 after buying an additional 14,260 shares in the last quarter. Founders Financial Alliance LLC raised its position in Bristol Myers Squibb by 17.5% in the 3rd quarter. Founders Financial Alliance LLC now owns 9,452 shares of the biopharmaceutical company’s stock valued at $426,000 after buying an additional 1,407 shares during the last quarter. Skandinaviska Enskilda Banken AB publ lifted its stake in Bristol Myers Squibb by 59.9% in the 3rd quarter. Skandinaviska Enskilda Banken AB publ now owns 3,719,987 shares of the biopharmaceutical company’s stock valued at $167,771,000 after acquiring an additional 1,393,646 shares in the last quarter. Finally, denkapparat Operations GmbH boosted its position in Bristol Myers Squibb by 46.1% during the 3rd quarter. denkapparat Operations GmbH now owns 35,358 shares of the biopharmaceutical company’s stock worth $1,595,000 after acquiring an additional 11,154 shares during the last quarter. Institutional investors own 76.41% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on BMY. Leerink Partners lifted their price objective on shares of Bristol Myers Squibb from $54.00 to $60.00 and gave the company an “outperform” rating in a report on Tuesday, January 13th. Piper Sandler reissued an “overweight” rating and set a $66.00 price target (up from $62.00) on shares of Bristol Myers Squibb in a research report on Wednesday, January 28th. Scotiabank restated a “sector perform” rating and issued a $60.00 price objective (up previously from $53.00) on shares of Bristol Myers Squibb in a report on Friday, January 9th. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $57.00 target price (up previously from $51.00) on shares of Bristol Myers Squibb in a research report on Tuesday, December 2nd. Finally, Cantor Fitzgerald reissued a “neutral” rating on shares of Bristol Myers Squibb in a research report on Monday, November 24th. Eight equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $59.20.

Bristol Myers Squibb Price Performance

NYSE:BMY opened at $60.28 on Wednesday. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $63.33. The firm has a market capitalization of $122.76 billion, a price-to-earnings ratio of 17.47, a P/E/G ratio of 0.17 and a beta of 0.29. The stock’s 50 day moving average price is $55.70 and its two-hundred day moving average price is $49.72. The company has a quick ratio of 1.14, a current ratio of 1.26 and a debt-to-equity ratio of 2.32.

Bristol Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing the consensus estimate of $1.65 by ($0.39). Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The business had revenue of $12.50 billion for the quarter, compared to the consensus estimate of $12.24 billion. During the same quarter in the prior year, the firm posted $1.67 earnings per share. The business’s revenue was up 1.3% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, analysts anticipate that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, February 2nd. Stockholders of record on Friday, January 2nd were paid a dividend of $0.63 per share. The ex-dividend date was Friday, January 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.2%. This is a boost from Bristol Myers Squibb’s previous quarterly dividend of $0.62. Bristol Myers Squibb’s dividend payout ratio is 73.04%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.